Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 2Tuberous Sclerosis Complex-associated Refractory Seizures 1Kidney Neoplasms 1Graft vs Host Disease 1Bronchiolitis Obliterans Syndrome 1

Interventions

Sunitinib 7Nivolumab 4pembrolizumab 3cabozantinib 2Ipilimumab 2Everolimus 2Axitinib 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1sacituzumab govitecan 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1lenvatinib 1larotrectinib 1ipatasertib 1erdafitinib 1entrectinib 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1belzutifan 1avelumab 1adavosertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Carcinoma, Renal Cell × Everolimus × Clear all
NCT04195750 2026-05-14

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
755 enrolled 28 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02811861 2026-02-23

CLEAR

Eisai Inc.

Phase 3 Active not recruiting
1,069 enrolled 12 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡